Skip to main content
Premium Trial:

Request an Annual Quote

DVS Sciences Collaborating with Cytobank on Informatics Tools for CyTOF Platform

Premium

DVS Sciences, developer of the CyTOF mass cytometry platform, this week announced a business agreement with flow cytometry informatics firm Cytobank to develop a cloud-based informatics platform for managing and analyzing CyTOF data.

Named DVS Cytobank, the platform will be released to early-access customers in August with a wide commercial release planned for November. Financial and other details of the agreement were not disclosed.

Combining capabilities of flow cytometry and atomic mass spectrometry, the CyTOF is able to simultaneously quantify as many as 100 protein biomarkers in individual cells at a rate of roughly 1,000 cells per second.

These capabilities make it a potentially valuable tool for large-scale proteomic studies, such as one published in Science last year by Stanford University researcher Garry Nolan (PM 5/13/2011). It also creates a need for informatics tools capable of processing and analyzing such massive quantities of data.

“The marriage of uniquely informative data acquired by our CyTOF instruments and reagents with the powerful capabilities of the Cytobank cloud-based platform will be enabling for our researchers around the world as they analyze, manage, and share large amounts of multi-parameter data,” Joseph Victor, president and CEO of DVS, said in a statement.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more